Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Open Label, Dose Escalation Study of IOA-289, an Orally Bioavailable, Selective Autotaxin (ENPP2) Inhibitor Alone and in Combination with Gemcitabine/nab-paclitaxel in Patients with Metastatic Pancreatic Cancer

Next Previous
Trial Profile

A Phase 1b, Open Label, Dose Escalation Study of IOA-289, an Orally Bioavailable, Selective Autotaxin (ENPP2) Inhibitor Alone and in Combination with Gemcitabine/nab-paclitaxel in Patients with Metastatic Pancreatic Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; IOA 289 (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
  • Focus Adverse reactions
  • Acronyms AION-01; AION-02
  • Sponsors iOnctura

Most Recent Events

  • 14 Oct 2025 Primary endpoint has been met. (Anti-tumor responses)
  • 14 Oct 2025 According to an iOnctura media release, data are being presented as a poster at the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany.
  • 14 Oct 2025 Results published in the Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top